Does Rallies show Form 4 insider transactions for AURA?

Yes. Rallies tracks AURA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AURA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AURA. It does not provide personalized investment advice.

AURA (Aura Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Aura Biosciences, Inc. Common Stock (AURA) is a publicly traded Healthcare sector company. As of May 21, 2026, AURA trades at $8.00 with a market cap of $772.30M and a P/E ratio of -4.26. AURA moved +1.15% today. Year to date, AURA is +44.21%; over the trailing twelve months it is +25.97%. Its 52-week range spans $4.35 to $12.38. Analyst consensus is strong buy with an average price target of $19.75. Rallies surfaces AURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AURA stock inside the company?

Recent AURA insider activity includes Kilroy Conor sold 11.74K, Kilroy Conor sold 12.08K, Plavsic Mark sold 15.89K, Hopkins Janet Jill sold 20.40K, and Elazzouzi Amy sold 8.55K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AURA Key Metrics

Key financial metrics for AURA
Metric	Value
Price	$8.00
Market Cap	$772.30M
P/E Ratio	-4.26
EPS	$-1.76
Dividend Yield	0.00%
52-Week High	$12.38
52-Week Low	$4.35
Volume	444.64K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-106.19M
Gross Margin	0.00%

Recent AURA Insider Trades

Kilroy Conor sold 11.74K (~$82.40K) on Apr 16, 2026.
Kilroy Conor sold 12.08K (~$61.00K) on Feb 17, 2026.
Plavsic Mark sold 15.89K (~$80.24K) on Feb 17, 2026.
Hopkins Janet Jill sold 20.40K (~$103.23K) on Feb 17, 2026.
Elazzouzi Amy sold 8.55K (~$43.26K) on Feb 17, 2026.

Latest AURA News

Aura Biosciences Raises $299 Million, Extends Cash Runway into 2H 2028 — May 11, 2026
Aura Biosciences Launches Stock Offering with Pre-Funded Warrants, 15% Overallotment Option — May 4, 2026
Aura Biosciences Raises $144.2M, Expects CoMpass Enrollment by Mid-2026 — Mar 30, 2026
Aura Biosciences Secures FDA SPA for Phase 3 Bel-sar Trial, Expects Mid-Year Bladder Data — Mar 5, 2026
Aura Biosciences’ EPS Estimate Up 5.9%, YTD Return 2.2% — Feb 16, 2026

AURA Analyst Consensus

5 analysts cover AURA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.75.

Common questions about AURA

Who is trading AURA stock inside the company?: Recent AURA insider activity includes Kilroy Conor sold 11.74K, Kilroy Conor sold 12.08K, Plavsic Mark sold 15.89K, Hopkins Janet Jill sold 20.40K, and Elazzouzi Amy sold 8.55K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AURA?: Yes. Rallies tracks AURA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AURA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AURA. It does not provide personalized investment advice.